Neonatal antibody titers against varicella-zoster virus in relation to gestational age, birth weight, and maternal titer.
Pediatrics
; 109(1): 79-85, 2002 Jan.
Article
in En
| MEDLINE
| ID: mdl-11773545
ABSTRACT
OBJECTIVE:
Varicella-zoster virus (VZV) can cause severe disease in premature neonates. The fetus receives protective maternal VZV-immunoglobulin G (IgG) mainly in the third trimester of pregnancy. Therefore, premature neonates are considered at risk for VZV infection. Administration of varicella-zoster immunoglobulin (VZIG) within 96 hours after exposure effectively prevents severe illness in susceptible patients. The objectives of this study were to define the major determinants of the neonatal VZV-IgG titer and to determine the half-life of transplacentally acquired VZV-IgG. Guidelines provided by the Centers for Disease Control and Prevention for the use of VZIG in (premature) neonates were evaluated.METHODS:
VZV-IgG titers were measured in sera of 221 neonates and 43 mothers using a quantitative enzyme-linked immunosorbent assay. In 27 neonates, VZV-IgG titers were followed for up to 14 weeks.RESULTS:
In a linear regression model, the maternal antibody titer was the major determinant of the neonatal titer (beta = 0.89); gestational age was only of minor importance (beta = 0.18). The median half-life of VZV-IgG in neonates was 25.5 days (range 14.6-76.0 days). In the first weeks of life, major fluctuations of the VZV-IgG titer occurred in >50% of the neonates. The predictive value of Centers for Disease Control and Prevention guidelines for identification of neonates who should receive VZIG in case of exposure to VZV was poor positive and negative predictive values were 0.80 and 0.43, respectively.CONCLUSIONS:
The neonatal VZV-IgG titer is predominantly predicted by the maternal VZV-IgG titer, whereas birth weight and gestational age are much less predictive than previously reported.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Infant, Premature
/
Herpesvirus 3, Human
/
Immunity, Maternally-Acquired
/
Antibodies, Viral
Type of study:
Evaluation_studies
/
Guideline
/
Prognostic_studies
Limits:
Humans
/
Infant
/
Newborn
Language:
En
Journal:
Pediatrics
Year:
2002
Document type:
Article
Affiliation country:
Netherlands